Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corp (NYSE: EW) delivers transformative medical technologies for heart valve disease and critical care monitoring. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in lifesaving innovations.
Track all official press releases, financial announcements, and clinical milestones in one centralized location. Our curated collection includes updates on transcatheter valve therapies, hemodynamic monitoring systems, regulatory approvals, and global partnership initiatives.
Stay informed about quarterly earnings, R&D breakthroughs, and strategic expansions shaping EW’s leadership in cardiovascular care. Bookmark this page for direct access to verified information supporting informed analysis of Edwards Lifesciences’ market position.
Edwards Lifesciences announced the sale of its Critical Care product group to BD (Becton, Dickinson and Company) for $4.2 billion in cash. The transaction will enhance Edwards' financial flexibility and enable strategic investments in structural heart disease technologies. The deal is expected to close by the end of 2024, pending regulatory approvals. Edwards aims to focus on advancing innovations in aortic, mitral, tricuspid, and pulmonic treatments. The sale is anticipated to have an immaterial impact on adjusted EPS in 2024.
BD (Becton, Dickinson and Company) has announced an agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition aims to expand BD's portfolio of smart connected care solutions and enhance its position in advanced monitoring technologies.
Critical Care, a global leader in advanced patient monitoring, generated over $900 million in revenue in 2023 and employs approximately 4,500 people. The acquisition is expected to be immediately accretive to BD's revenue growth, adjusted gross and operating margins, and adjusted earnings per share.
Critical Care will operate as a separate business unit within BD's Medical segment and will continue to be based in Irvine, California, under the leadership of Katie Szyman. The transaction is expected to close by the end of the calendar year, subject to regulatory reviews and closing conditions.
BD plans to fund the acquisition with a combination of $1 billion in cash and $3.2 billion in new debt. The company expects to achieve additional margin expansion and value through cost synergies and efficiencies.
Edwards Lifesciences has launched the SAPIEN 3 Ultra RESILIA valve in Europe, incorporating breakthrough RESILIA tissue technology for enhanced durability. The valve received CE Mark for patients with heart valve disease, with RESILIA tissue offering potential for extended durability. The valve aims to improve quality of life and future treatment options with lower rates of paravalvular leak and larger effective orifice areas. The technology is backed by 7-year COMMENCE Study data showing excellent outcomes. RESILIA tissue is a result of 20 years of research, indicating Edwards' focus on patient-centric technology.